Document is current
Any future updates will be listed below
-
Authors
Lee, Hyemin https://orcid.org/0000-0002-7387-5452
Horbath, Amber https://orcid.org/0000-0003-1482-8637
Kondiparthi, Lavanya
Meena, Jitendra Kumar https://orcid.org/0000-0003-0199-9357
Lei, Guang https://orcid.org/0000-0002-3282-0666
Dasgupta, Shayani
Liu, Xiaoguang https://orcid.org/0000-0001-6977-5128
Zhuang, Li
Koppula, Pranavi https://orcid.org/0000-0002-7567-1891
Li, Mi https://orcid.org/0000-0002-6038-4144
Mahmud, Iqbal https://orcid.org/0000-0001-7729-8122
Wei, Bo
Lorenzi, Philip L. https://orcid.org/0000-0003-0385-7774
Keyomarsi, Khandan https://orcid.org/0000-0002-5440-0849
Poyurovsky, Masha V.
Olszewski, Kellen
Gan, Boyi https://orcid.org/0000-0001-8884-6040
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP230072)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA181196, R01CA244144, R01CA247992, R01CA269646, U54 CA274220)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 15 March 2023
Accepted: 12 December 2023
First Online: 2 January 2024
Competing interests
: B.G. reports receiving consultation fees from Guidepoint Global, Cambridge Solutions, and NGM Bio, and is an inventor with patent applications involving targeting ferroptosis in cancer therapy. K.O. and L.K. are former full-time employees of Kadmon Corporation and are now full-time employees of the Carl Icahn Labs and Sanofi, US, respectively. M.V.P. is a former full-time employee of Kadmon Corporation and is now a full-time employee at PMV Pharmaceutics. The other authors declare no competing interests.
